CMHC Masterclass On Demand: Connecting the Dots in Cardiometabolic Medicine - Integrative Approaches to Improve Patient Care
Utilizing thought-provoking and interactive discussions, multidisciplinary experts in this masterclass cover advances in lifestyle, nutrition, genetics, and pharmacotherapy to prevent and address obesity, cardiovascular disease, hypertension, dyslipidemia, type 2 diabetes, kidney disease and more. Each section will include expert panel discussions, which will aim to provide practical approaches to patient management and interpret the latest advances to patient care.
Target Audience
The educational design of this activity addresses the needs of US-based healthcare professionals, including primary care clinicians (PCPs), cardiologists, integrative medicine clinicians, registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals.
Learning Objectives
After completing this activity, the participant should be better able to:
- Discuss the interrelationships among cardiometabolic risk factors and their impact on the development of cardiometabolic diseases, including diabetes, dyslipidemia, hypertension, obesity, kidney disease, and cardiovascular disease.
- Review the latest evidence and guidelines for the prevention, screening, and treatment of the complex patient with cardiometabolic risk or cardiometabolic disease.
- Outline strategies aimed at timely screening and prevention of cardiometabolic disease.
- Summarize recent evidence for emerging therapies in order to stay current with the most recent updates in the cardiometabolic field.
- Select comprehensive treatment regimens for patients with cardiometabolic disease that utilize both lifestyle interventions and pharmacotherapy to improve outcomes.
- Recognize obesity as a disease and the importance of long-term weight loss as an important therapeutic target in patients with type 2 diabetes and obesity.
- Select antiglycemic therapies with a favorable profile on weight and weight management in patients with obesity and type 2 diabetes when appropriate.
- Review the efficacy and safety of current, new, and emerging therapies for long-term weight management in patients with type 2 diabetes and obesity.
- Select individualized treatment options that optimize glycemic and weight control in patients with obesity and type 2 diabetes based on available options, recommendations, and patient preferences.
Mark C. Houston, MD, MS, MSc, FACP, FAHA, FASH, (Co-Chair)
FACN FAARM ABAARM DABC
Associate Clinical Professor of Medicine
Vanderbilt University Medical School 1990-2012
Director, Hypertension Institute and Vascular Biology
Medical Director of Division of Human Nutrition
Saint Thomas Medical Group, Saint Thomas Hospital
Nashville, TN
George L. Bakris, MD, FASN, FAHA (Co-Chair)
Professor of Medicine
Director, Am. Heart Assoc. Comprehensive Hypertension Center
Department of Medicine
University of Chicago Medicine
Chicago, IL
Christie M. Ballantyne, MD
Baylor College of Medicine
Houston, TX
Jennifer Green, MD
Professor of Medicine, Division of Endocrinology
Duke University School of Medicine
Duke Clinical Research Institute
Durham, NC
Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC
Associate Director of Preventive Cardiology
Associate Professor of Medicine and Epidemiology
Division of Cardiology
Johns Hopkins School of Medicine
Co-Editor in Chief
The American Journal of Preventive Cardiology
Baltimore, MD
Deanna Minich, MS, PhD, FACN, CNS
Fellow, American College of Nutrition
University of Western States, Adjunct Faculty
Institute for Functional Medicine, Adjunct Faculty
Seattle, WA
Kristina S. Petersen PhD, APD, FAHA
Assistant Professor, Department of Nutritional Sciences
Texas Tech University
Lubbock, TX
Ileana L. Piña, MD, MPH, FAHA, FACC, FHFSA
Professor of Medicine, Thomas Jefferson University
Clinical Professor of Medicine, Central Michigan University
Adjunct Professor of Epi/Biostats, Case Western Reserve University
Detroit, MI
Dr. Joseph Pizzorno, ND
Editor, Integrative Medicine: A Clinician’s Journal
Co-Author, Clinical Environmental Medicine
Seattle, WA
Donna H. Ryan, MD
Professor Emerita
Pennington Biomedical Research Center
Baton Rouge,LA
Kumar Sharma, MD, FASN, FAHA
Hillis Chair in Medicine
Chief, Nephrology
Vice Chair of Research
University of Texas Health San Antonio
San Antonio, TX
Virend K. Somers MD, PhD
Alice Sheets Marriott Professor
Department of Cardiovascular Medicine
Mayo Clinic Rochester
Rochester, MN
Filomena Trindade, MD, MPH, ABOIM, ABFM, FAARM, IFMCP
The Institute for Functional Medicine (IFM)
Capitola, CA
Tracy Y. Wang, MD, MHS, MSc
Professor of Medicine
Duke University
Duke Clinical Research Institute
Durham, NC
Matthew R. Weir, MD
Professor and Director
Division of Nephrology
University of Maryland School of Medicine
Baltimore, MD
ESTIMATED TIME TO COMPLETE ACTIVITY
14 hours
JOINT PROVIDERSHIP STATEMENT
This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians
PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring for a maximum of 14 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 14 contact hours is provided by Global Education Group. For the advanced practice nurse, there are 1.3 total pharmacotherapy hours for this activity. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACIST ACCREDITATION STATEMENT
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Credit Designation
Global Education Group designates this continuing education activity for 14 contact hour(s) (1.4 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number (UAN): 0530-9999-22-096-H01-P
This is a knowledge-based activity.
DIETICIAN ACCREDITATION STATEMENT
Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 14 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012
CDR learners may submit their program evaluation directly to the CDR.
GLOBAL CONTACT INFORMATION
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com..
DISCLOSURES
Information on planner and faculty disclosures can be downloaded here
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
This activity is complimentary and available during the period June 27, 2022 through June 27, 2023. Learners should take the pre-test and review all recordings in order to access the evaluation, claim credit, and receive a CME/CE certificate.
For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org. For questions about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
Available Credit
- 14.00 ACPE Pharmacy
- 14.00 AMA PRA Category 1 Credit™
- 14.00 ANCC
- 14.00 CDE
- 14.00 Participation
Registration Fee
This activity is complimentary and available during the period June 27, 2022 through June 27, 2023. Learners should sign in or create an account first before registering for this course.
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.